Open AccessTrial of routine gonadotropin releasing hormone agonist treatment before abdominal hysterectomy for leiomyoma
Author(s) -
Balasch Juan,
Manau Dolors,
Mimó Jaime,
Duran Magda,
Puerto Bienvenido,
Vanrell Juan A.
Publication year - 1995
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.3109/00016349509024390
Subject(s) - medicine , hematocrit , hysterectomy , gonadotropin releasing hormone agonist , leiomyoma , agonist , triptorelin , uterine leiomyoma , surgery , randomized controlled trial , gynecology , gonadotropin releasing hormone , hormone , luteinizing hormone , receptor
Objective. To investigate the usefulness of a routine short term treatment with gonadotropin releasing hormone agonist (D‐Trp‐6‐LHRH depot) before abdominal hysterectomy for leiomyoma. Study Design. Prospective, comparative, randomized study. Setting. A teaching hospital of Barcelona University. Patients. Fifty premenopausal women requiring hysterectomy as treatment for symptomatic leiomyomas. Twenty‐three patients were randomized to receive gonadotropin releasing hormone agonist treatment before hysterectomy (cases), and 27 patients were randomized to immediate hysterectomy (controls). Main outcome measures. Type of abdominal incision, operating time, operative hemoglobin and hematocrit decrease, postoperative morbidity, and days in hospital. Results. In the agonist treated group mean uterine volume decreased and mean hemoglobin and hematocrit significantly rose after 8 weeks of treatment. Operative time was similar in both groups of patients but the number of women having Pfannenstiel incision was significantly higher in the cases. Mean operative hemoglobin and hematocrit decrease and postoperative morbidity were lower in the cases. There was a trend for shorter postoperative hospital stays in the agonist treated group. Conclusions. Our results favor the routine use of a short term gonadotropin releasing hormone agonist treatment before abdominal hysterectomy for leiomyoma in order to decrease operative blood loss and postoperative morbidity.